BIOCITECH, France, November 13 2007 – Cellectis S.A. (Alternext: ALCLS), the genome engineering company developing a new range of custom DNA rewriting products for the healthcare, research and industrial sectors, today announced a turnover of €161K for the third quarter of 2007. These revenues come from annual fees and royalties due on turnover under the terms of the company’s industrial agreements. In parallel, subsidies received rose by €351K. Hence, operating income for the first 9 months of the year amounted to just over €2 million.
